Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to 0.3%.

  • BioNexus Gene Lab's Return on Capital Employed fell 2100.0% to 0.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.3%, marking a year-over-year decrease of 2100.0%. This contributed to the annual value of 0.18% for FY2024, which is 1300.0% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Return on Capital Employed is 0.3%, which was down 2100.0% from 0.39% recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Return on Capital Employed high stood at 0.14% for Q4 2021, and its period low was 0.39% during Q2 2025.
  • In the last 5 years, BioNexus Gene Lab's Return on Capital Employed had a median value of 0.08% in 2023 and averaged 0.1%.
  • As far as peak fluctuations go, BioNexus Gene Lab's Return on Capital Employed tumbled by -10600bps in 2021, and later soared by 2800bps in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Return on Capital Employed stood at 0.14% in 2021, then crashed by -132bps to 0.05% in 2022, then crashed by -469bps to 0.26% in 2023, then soared by 32bps to 0.18% in 2024, then crashed by -67bps to 0.3% in 2025.
  • Its Return on Capital Employed stands at 0.3% for Q3 2025, versus 0.39% for Q2 2025 and 0.25% for Q1 2025.